AI Article Synopsis

  • * In a study comparing 25 pediatric melanoma samples to those from young and older adults, researchers found significantly lower levels of PRAME expression in pediatric cases, indicating age-dependency in marker expression.
  • * The findings suggest that relying on PRAME as a diagnostic or therapeutic option in pediatric melanoma may be problematic due to its low expression, highlighting the need for tailored approaches in treating younger patients.

Article Abstract

Pediatric melanomas are rare tumors that have clinical and histological differences from adult melanomas. In adult melanoma, the immunohistochemical marker PRAME is increasingly employed as a diagnostic adjunct. PRAME is also under investigation as a target structure for next-generation immunotherapies including T-cell engagers. Little is known about the characteristics of PRAME expression in pediatric melanoma. In this retrospective study, samples from 25 pediatric melanomas were compared with control groups of melanomas in young adults (18-30 years; n = 32), adult melanoma (>30 years, n = 30), and benign melanocytic nevi in children (0-18 years; n = 30) with regard to the immunohistochemical expression of PRAME (diffuse PRAME expression >75%/absolute expression). Pediatric melanomas show lower diffuse PRAME expression (4%) and lower absolute PRAME expression (25%) compared to young adult melanomas (15.6%/46.8%) and adult melanomas (50%/70%). A significant age-dependent expression could be observed. An analysis of event-free survival shows no prognostic role for PRAME in pediatric melanoma and young adult melanoma, but a significant association with diffuse PRAME expression in adulthood. The age dependency of PRAME expression poses a potential pitfall in the diagnostic application of melanocytic tumors in young patients and may limit therapeutic options within this age group. The immunohistochemical expression of the tumor-associated antigen PRAME is an increasingly important diagnostic marker for melanocytic tumors and is gaining attention as a possible immunotherapeutic target in melanoma. As the available data primarily stem from adult melanoma, and given the clinical and histological distinctions in pediatric melanomas, our understanding of PRAME expression in this specific patient group remains limited. The age-dependent low PRAME expression shown here constrains the use of this marker in pediatric melanoma and may also limit the use of immunotherapeutic strategies against PRAME in young patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.13167DOI Listing

Publication Analysis

Top Keywords

prame expression
32
adult melanoma
20
pediatric melanoma
16
pediatric melanomas
16
prame
14
expression
13
expression pediatric
12
adult melanomas
12
diffuse prame
12
melanoma
10

Similar Publications

ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new.

Virchows Arch

December 2024

Department of Pathology, University of California San Diego Health, 9300 Campus Point Drive, Suite 1-200, La Jolla, MC 7723, San Diego, CA, 92037, USA.

A distinctive subset of uterine mesenchymal tumors display recurrent genetic fusions involving receptor tyrosine kinases, including NTRK, PDGFB, FGFR1, and RET, presumably leading to aberrant pathway activation. A pair of recent studies have highlighted the existence of a genetic fusion-negative uterine sarcoma that is characterized by activating mutations in ERBB2/ERBB3, CDKN2A deletion, inactivating ATRX mutation, and a S100 + /SOX10 + immunohistochemical profile. This report describes another case of this emerging entity that was diagnosed in a 57-year-old woman.

View Article and Find Full Text PDF

Background: PRAME (eferentially expressed ntigen in lanoma) is a cancer-testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME tumors could be a novel immunotherapeutic option.

View Article and Find Full Text PDF

The Influence of Melanoma Extracellular Vesicles on Benign Melanocytes: A Role for PRAME in Modulation of the Tumor Microenvironment.

J Invest Dermatol

November 2024

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Cancer Biology Research Program, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA. Electronic address:

Article Synopsis
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!